About Delix Therapeutics
Delix Therapeutics is a company based in Menlo Park (United States) founded in 2019 by Nicholas Haft and David E Olson.. Delix Therapeutics has raised $70 million across 5 funding rounds from investors including Comerica, HHS and RA Capital. The company has 7 employees as of December 31, 2021. Delix Therapeutics offers products and services including Neuroplastogens. Delix Therapeutics operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
- Headquarter Menlo Park, United States
- Employees 7 as on 31 Dec, 2021
- Founders Nicholas Haft, David E Olson
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Delix Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$70 M (USD)
in 5 rounds
-
Latest Funding Round
$825 K (USD), Grant
Jun 04, 2024
-
Investors
Comerica
& 20 more
-
Employee Count
7
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Delix Therapeutics
Delix Therapeutics offers a comprehensive portfolio of products and services, including Neuroplastogens. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Compounds that induce neuroplasticity to treat brain health conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Delix Therapeutics
Delix Therapeutics has successfully raised a total of $70M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $825 thousand completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $825,000
-
First Round
First Round
(27 Sep 2021)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Grant - Delix Therapeutics | Valuation |
investors |
|
| Sep, 2023 | Amount | Grant - Delix Therapeutics | Valuation |
investors |
|
| Jan, 2022 | Amount | Debt – Convertible - Delix Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Delix Therapeutics
Delix Therapeutics has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Comerica, HHS and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are invested in by Artis Ventures.
|
Founded Year | Domain | Location | |
|
Investment in cannabis industry startups is facilitated by Casa Verde.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Delix Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Delix Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Delix Therapeutics Comparisons
Competitors of Delix Therapeutics
Delix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| domain | founded_year | HQ Location |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| domain | founded_year | HQ Location |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| domain | founded_year | HQ Location |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Delix Therapeutics
Frequently Asked Questions about Delix Therapeutics
When was Delix Therapeutics founded?
Delix Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Delix Therapeutics located?
Delix Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Is Delix Therapeutics a funded company?
Delix Therapeutics is a funded company, having raised a total of $70M across 5 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $30M, raised on Sep 27, 2021.
How many employees does Delix Therapeutics have?
As of Dec 31, 2021, the latest employee count at Delix Therapeutics is 7.
What does Delix Therapeutics do?
Delix Therapeutics was founded in 2019 and is based in Menlo Park, United States. Small molecule-based, non-hallucinogenic versions of psychedelic compounds are developed by the company to address depression, anxiety, and post-traumatic stress disorders. Operations focus on creating therapeutic solutions within the biotechnology sector for multiple neurological conditions, enabling treatment options for healthcare providers.
Who are the top competitors of Delix Therapeutics?
Delix Therapeutics's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
What products or services does Delix Therapeutics offer?
Delix Therapeutics offers Neuroplastogens.
Who are Delix Therapeutics's investors?
Delix Therapeutics has 21 investors. Key investors include Comerica, HHS, RA Capital, Artis Ventures, and Casa Verde.